VYNE Therapeutics (VYNE) EBT (2017 - 2026)
VYNE Therapeutics (VYNE) posted EBT of -$3.6 million for Q1 2026, up 37.62% on a QoQ basis from -$5.7 million in Q2 2025, and up 58.33% year-over-year from -$2.3 million in Q1 2025.
VYNE Therapeutics (VYNE) EBT (2017 - 2026) Analysis & Trends
VYNE Therapeutics' EBT history runs 10 years deep, the most recent figure standing at -$3.6 million for Q1 2026.
- Quarterly EBT rose 58.33% year-over-year to -$3.6 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was -$29.9 million (up 28.98% YoY) and the FY2025 annual result came in at -$26.7 million, up 32.84% from the prior year.
- EBT was -$3.6 million for Q1 2026 at VYNE Therapeutics, up from -$5.7 million in the prior quarter.
- Across five years, EBT topped out at -$3.6 million in Q1 2026 and bottomed at -$12.2 million in Q3 2024.
- A 5-year average of -$8.0 million and a median of -$8.2 million in 2022 frame the typical range for EBT.
- Annual changes were most pronounced in 2024 — EBT slumped 100.25% — and 2026, when it jumped 58.33%.
- VYNE Therapeutics' EBT stood at -$7.7 million in 2022, then increased by 20.6% to -$6.2 million in 2023, then sank by 95.22% to -$12.0 million in 2024, then soared by 52.15% to -$5.7 million in 2025, then surged by 37.62% to -$3.6 million in 2026.
- Business Quant data shows VYNE's EBT at -$3.6 million in Q1 2026, -$5.7 million in Q2 2025, and -$8.6 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | -36.97 Mn |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | -15.31 Mn |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 259.22 Mn |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 1.25 Bn |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 831.20 Mn |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | 541.00 Mn |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | -453.82 Mn |
| 10 | VYNE Therapeutics | 1.19 Bn | 1.16 Bn | - | -3.59 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -3.59 Mn |
| Jun 30, 2025 | -5.75 Mn |
| Mar 31, 2025 | -8.60 Mn |
| Dec 31, 2024 | -12.01 Mn |
| Sep 30, 2024 | -12.16 Mn |
| Jun 30, 2024 | -9.40 Mn |
| Mar 31, 2024 | -6.24 Mn |
| Dec 31, 2023 | -6.15 Mn |
| Sep 30, 2023 | -6.07 Mn |
| Jun 30, 2023 | -10.04 Mn |
| Mar 31, 2023 | -5.61 Mn |
| Dec 31, 2022 | -7.75 Mn |
| Sep 30, 2022 | -9.26 Mn |
| Jun 30, 2022 | -8.24 Mn |
| Mar 31, 2022 | -8.69 Mn |
| Dec 31, 2021 | -8.82 Mn |
| Sep 30, 2021 | -14.28 Mn |
| Jun 30, 2021 | -10.69 Mn |
| Mar 31, 2021 | -10.88 Mn |
| Dec 31, 2020 | -23.18 Mn |